Development of a Supersaturable SEDDS (S-SEDDS) Formulation of Paclitaxel with Improved Oral Bioavailability

Journal of Pharmaceutical Sciences

Volumn 92, Issue 12, 2003, Pages 2386-2398

  Gao, Ping ^a   Rush, Bobby D ^a   Pfund, William P ^a   Huang, Tiehua ^a   Bauer, Juliane M ^a   Morozowich, Walter ^a   Kuo, Ming Shang ^a   Hageman, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

Bioavailability; Emulsion microemulsion; Hydroxypropyl methylcellulose; Oral absorption; Paclitaxel; Precipitation; Solubility; Supersaturation

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; GELATIN; GLYCEROL DIOLEATE; GLYCOPROTEIN P; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 400; PACLITAXEL; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; MALE; MICROEMULSION; NONHUMAN; PRECIPITATION; RAT;

EID: 0344012523     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10511     Document Type: Article

References (34)

1. Pinnamaneni S, Das NG, Das SK. 2002. Formulation approaches for orally administrated poorly soluble drugs. Phamazie 57(5):291-300.
2. Bagwe RP, Kanicky JR, Palla BJ, Patanjali PK, Shah DO. 2001. Improved drug delivery using microemulsions: Rationale, recent progress, and new horizons. Crit Rev Ther Drug Carrier Syst 18(1):77-140.
3. Wasan KM. 2001. Formulations and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Devel Ind Pharm 27(4):267-276.
4. Charman WN. 2000. Lipids, lipophilic drugs and oral drug delivery-Some emerging concepts. J Pharm Sci 89:967-978.
5. Pouton CW. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 11(Suppl. 2): S93-S98.
6. Poelma FGJ, Breas R, Tukker JJ, Crommelin DJA. 1991. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacol 43(5):317-324.
7. Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturable formulations. Drug Devel Ind Pharm, submitted.
8. Pellet MA, Davis AF, Hadgraft J. 1994. Effect of supersaturation on membrane transport: 2. Piroxicam. Int J Pharm 111:1-6.
9. Pellet MA, Castellano S, Hadgraft J, Davis AF. 1997. The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro. J Controlled Release 46:205-214.
10. Pellet MA, Roberts MS, Hadgraft J. 1997. Supersaturated solutions evaluated with an intro stratum corneum tape stripping technique. Int J Pharm 151:91-98.
11. Usui F, Maeda K, Kusai A, Nishimura K, Yamamoto K. 1997. Inhibitory effects of water soluble polymers on precipitation of RS-8359. Int J Pharm 154:59-66.
12. Suzuki H, Sunada H. 1997. Comparison of nicotiamide, ethylurea and polyethylene glycol as carriers for nifedipine solid dispersion systems. Chem Pharm Bull 45(10):1688-1693.
13. Suzuki H, Sunada H. 1998. Some factors influencing the dissolution of solid dispersions with nicotiamide and hydroxypropylmethycellulose as combined carriers. Chem Pharm Bull 46(6):1015-1020.
14. Yamada T, Saito N, Imai T, Otagiri M. 1999. Effect of grinding with hydroxypropyl cellulose on dissolution and particle size of a poorly water-soluble drug. Chem Pharm Bull 47(9):1311-1313.
15. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S, Miyazaki K. 1999. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159-164.
16. Raghavan RL, Trividic A, Davis AF, Hadgraft J. 2000. Effects of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm 193:231-237.
17. Iervolino M, Raghavan RL, Hadgraft J. 2000. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 198:229-238.
18. Iervolino M, Cappello B, Raghavan RL, Hadgraft J. 2001. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm 212:131-141.
19. Lee J, Lee SC, Acharya G, Chang C, Park K. 2003. Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm Res 20(7):1022-1030.
20. Straubinger RM. 1995. Biopharmaceutics of paclitaxel (Taxol): Formulation, activity, and pharmacokinetics. In: Suffness M, editor. Taxol science and applications. New York: CRC Press.
21. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. 1992. Synthesis and evaluation of some water-insoluble prodrugs and derivatives of Taxol with antitumor activity. J Med Chem 35:145.
22. Nuijen B, Bouma M, Schellens JHM, Beijnen JH. 2001. Progress in the development of alternative pharmaceutical formulations of taxanes. Investigational New Drugs 19:143-153.
23. Trissel LA, editor. 1994. Handbook on injectable drugs, 8th ed. Bethesda, MD: American Society of Hospital Pharmacists, Inc., p 808.
24. Zuylen LV, Verweij J, Sparreboom A. 2001. Role of formulation vehicles in taxane pharmacology. Investigational New Drugs 19:125-141.
25. Lassus M, Scott D, Leyland JB. 1985. Allergic reactions associated with Cremophor containing antineoplastics. Proc Am Soc Clin Oncol 4:268.
26. Malingre MM, Beijnen JH, Schellens JHM. 2001. Oral delivery of taxanes. Investigational New Drugs 19:155-162.
27. Bardeleijer HA, Tellingen OV, Schellens JHM, Beijnen JH. 2000. The oral route of the administration of cytotoxic drugs: Strategies to increase the efficiency and consistency of drug delivery. Investigational New Drugs 18:231-241.
28. Terwogt JMM, Malingre MM, Beijnen JH, Huinink WWTB, Rosing H, Koopman FJ, Tellingen OV, Swart M, Schllens JHM. 1999. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384.
29. Malingre MM, Beijnen JH, Rosing H, Koopman KF, Tellingen OV, Duchin K, Huinink WWTB, Swart M, Leiverst J, Schellens JHM. 2001. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 47:347-354.
30. Woo JS, Lee CH, Shim CK, Hwang S-J. 2003. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30.
31. Montaseri H, Jamali F, Micetich RG, Daneshtalab M. 1995. Improving oral bioavailability of Taxol. Pharm Res 12:S-429.
32. Poelma FGJ, Breas R, Tukker JJ, Crommelin DJA. 1991. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacokinet 43(5):317-324.
33. Poelma FGJ, Breas R, Tukker JJ, Josef J. 1990. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm Res 7(4):392-397.
34. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. 2003. Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 20(5):749-756.